Le produit a bien été ajouté au panier.

discount label
H-SNTSESF-NH2
Vue en 3D

Biosynth logo

H-SNTSESF-NH2

Ref. 3D-PP48195

Taille indéfinieÀ demander
Livraison estimée en/au États-Unis, le mardi 5 novembre 2024

Informations sur le produit

Nom :
H-SNTSESF-NH2
Description :

Peptide H-SNTSESF-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNTSESF-NH2 include the following: Nanomedicine strategies for heating"cold" ovarian cancer (OC): next evolution in immunotherapy of OC Y Yang, T Zhao, Q Chen, Y Li, Z Xiao - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202202797 A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy W Zhang, D Li, X Xu, Y Chen, X Shi - Advanced , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202202977 Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway T Wang, X Wu, C Guo, K Zhang, J Xu - Journal of medicinal , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00990 The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides Attached R Shrestha , EV Petley, KJ Farrand - , 2020 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000221 The synthesis of potential drug candidates based on the PEE-G dendrimer scaffold R Shrestha - 2019 - openaccess.wgtn.ac.nzhttps://openaccess.wgtn.ac.nz/articles/thesis/The_synthesis_of_potential_drug_candidates_based_on_the_PEE-G_dendrimer_scaffold/22777214 PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules Q Geng, P Jiao, P Jin, G Su, J Dong - Current Pharmaceutical , 2017 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2017/00000023/00000039/art00008 PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy PG Sasikumar, NS Sudarshan, S Adurthi - Communications , 2021 - nature.comhttps://www.nature.com/articles/s42003-021-02191-1 [68Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study M Zhou, S Xiang, Y Zhao , Y Tang , J Yang, X Yin - European Journal of , 2024 - Springerhttps://link.springer.com/article/10.1007/s00259-023-06447-2 A Plant Virus Nanoparticle Toolbox to Combat Cancer K Hefferon, M Shahgolzari , A Yavari - pharmafocusasia.comhttps://www.pharmafocusasia.com/research-development/plant-virus-nanoparticle-toolbox Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor J Liu, G Wang, L Liu, R Wu, Y Wu, C Fang, X Zhou - Scientific reports, 2019 - nature.comhttps://www.nature.com/articles/s41598-019-54231-w Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy H Peng, X He, Q Wang - Frontiers in Immunology, 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1035997/full Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer G Kandasamy, Y Karuppasamy , UM Krishnan - Vaccines, 2023 - mdpi.comhttps://www.mdpi.com/2076-393X/11/2/458 Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy E Khatoon, D Parama , A Kumar , MS Alqahtani - Life Sciences, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0024320522005276 VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses C Wu, X Cao , X Zhang - RSC Medicinal Chemistry, 2021 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2021/md/d1md00185j CA-170-a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik , L Skalniak , K Magiera-Mularz - Molecules, 2019 - mdpi.comhttps://www.mdpi.com/1420-3049/24/15/2804 Virus-like particles: a self-assembled toolbox for cancer therapy A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials Today , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2468519422000374 Materials Today Chemistry A Shahrivarkevishahi , LM Hagge, OR Brohlin - Materials , 2022 - labs.utdallas.eduhttps://labs.utdallas.edu/gassensmith/files/2022/03/1-s2.0-S2468519422000374-main.pdf Chemically Tuned Virus Like Particles: From Cancer Therapy to Targeted Delivery A Shahrivarkevishahi - 2021 - utd-ir.tdl.orghttps://utd-ir.tdl.org/items/2c22f8e6-d588-43ac-95a3-5f2fced7a7e8 Plant viral nanoparticle conjugated with anti-PD-1 peptide for ovarian cancer immunotherapy A Gautam, V Beiss, C Wang , L Wang - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/18/9733

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP48195 H-SNTSESF-NH2

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".